Replies to post #4320 on Ariad Pharmaceuticals Inc fka ARIA

[gpo344]

So no doubt Ponatinib will be used for the T315 mutation, but is that enough of a monetary return that it would cause Ariad to be worth the numbers that are being thrown around? Are there other indications that would propel it to the top of the list?

[biotech_researcher]

IMHO, even more important, is that preliminary phase I results indicate, that Pona can arrest/block the T315I mutation from mutating in the first place. In other words, with Pona, you lessen the chance in developing the T315I mutation. Read that information in the last Pona update. That will certainly cause Pona to move to the first level of treatment for certain CML patients. Some doctors will provide their patients the Lexus treatment..